Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 5,487 shares, a decrease of 86.6% from the July 30th total of 41,083 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 46,742 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Trading of Aprea Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in Aprea Therapeutics in the fourth quarter valued at about $40,000. DRW Securities LLC acquired a new position in Aprea Therapeutics during the fourth quarter worth about $103,000. Finally, AIGH Capital Management LLC lifted its holdings in shares of Aprea Therapeutics by 174.1% in the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after acquiring an additional 645,000 shares during the last quarter. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE traded down $0.12 during trading hours on Thursday, hitting $0.86. 1,168,292 shares of the stock were exchanged, compared to its average volume of 1,007,409. The company has a market cap of $10.83 million, a PE ratio of -0.80 and a beta of 1.52. The company’s fifty day simple moving average is $0.71 and its two-hundred day simple moving average is $0.77. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.69.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 47.60%. As a group, sell-side analysts expect that Aprea Therapeutics will post -0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Friday, July 17th. Wedbush decreased their price target on Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Finally, Oppenheimer began coverage on Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $3.07.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.